

ASX RELEASE

29 June 2022

**Annual General Meeting to be held Thursday 25 August 2022**

Amplia Therapeutics Limited (ASX: ATX) ('Amplia' or the 'Company') advises that its Annual General Meeting in respect of its financial year ended 31 March 2022 is to be held on Thursday 25 August 2022.

Details of the meeting venue and other meeting arrangements will be confirmed at a later date.

In accordance with ASX Listing Rule 14.3 nominations for the election of Directors must be received by the Company not later than Thursday 7 July 2022.

This ASX announcement was approved and authorised for release by the Company Secretary.

**For Further Information**

Dr. John Lambert  
Chief Executive Officer  
[john@ampliatx.com](mailto:john@ampliatx.com)  
[www.ampliatx.com](http://www.ampliatx.com)

**About Amplia Therapeutics Limited**

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).

- ENDS -